Acetazolamide as a chloride sparing Diuretic in patients Admitted with Heart Failure: a pilot and exploratory study (ADA-HF)

Hull University Teaching Hospitals NHS Trust0 个研究点目标入组 50 人开始时间: 2023年2月9日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1. Aged >18 years of any gender and able to give informed consent (females of child bearing age must consent to and have a negative pregnancy test prior to randomisation)
•2. Heart failure of any aetiology
•3. Admitted to hospital with a primary diagnosis of peripheral oedema caused by heart failure and deemed by treating clinicians to require treatment with intravenous diuretic.
•4. Patients are considered eligible as long as they are deemed to require standard of care (10mg per hour furosemide infusion).
•5. Patients whose medications have been discontinued for other reasons >1 week previously may be considered eligible. These medications include; high dose aspirin (>500mg / day), methotrexate, lithium, Sando-K®, sodium bicarbonate, other sodium tablets, oral steroids, or sodium valproate.
•6. Able to give informed written consent to participate in the trial.

•1. Unable to give informed written consent
•2. Allergy or contraindication to carbonic anhydrase inhibitors, or are taking another medication (other than loop diuretic) that has a diuretic effect such as bendroflumethiazide, metolazone or sodium-glucose linked transporter-2 inhibitors.
•3. Patient thought to be at end-of-life
•4. Concurrently taking thiazide (or thiazide-like) diuretic or sodium-glucose linked transporter-2 inhibitor
•5. Concurrently taking high dose aspirin (>500 mg/day), methotrexate, lithium, or sodium valproate – risk of drug interactions with ACZ
•6. Concurrently taking Sando-K®, oral sodium bicarbonate, or other sodium tablets – confounding electrolyte analysis
•7. Concurrently taking oral steroids – confounding diuretic analysis
•8. Peripheral oedema due to heart failure that has been triggered by an underlying illness such as severe anaemia (haemoglobin <8 g/DL) or concurrent severe infection (requiring intravenous antibiotics).
•9. SBP <80 mmHg at randomisation
•10. Serum sodium (severe hyponatraemia) <130 mmol/L at randomisation
•11. Serum potassium (hypokalaemia) <3.5 mmol/L at randomisation
•12. Serum chloride (severe hyperchloraemia) >110 mmol/L at randomisation
•13. Severe renal dysfunction with an eGFR (estimate glomerular filtration rate) result of <30 ml/min calculated by the Cockcroft-Gault formula
•14. Pregnant or intends to become pregnant whilst taking part in the trial

发起方